Dogwood Therapeutics DWTX Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Dogwood Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Dogwood Therapeutics’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dogwood Therapeutics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Dogwood Therapeutics's stock-based comp?
- Dogwood Therapeutics (DWTX) reported stock-based comp of $449.42K in Q1 2026.
- How has Dogwood Therapeutics's stock-based comp changed year-over-year?
- Dogwood Therapeutics's stock-based comp increased by 432.0% year-over-year, from $84.47K to $449.42K.
- What is the long-term trend for Dogwood Therapeutics's stock-based comp?
- Over 4 years (2021 to 2025), Dogwood Therapeutics's stock-based comp has grown at a 2.4% compound annual growth rate (CAGR), from $322.88K to $355.64K.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.